Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic potential. Vaccine development focuses on the principal target of the neutralizing humoral immune response, the spike (S) glycoprotei...

Bibliografiset tiedot
Päätekijät:	Watanabe, Y, Berndsen, ZT, Raghwani, J, Seabright, GE, Allen, JD, Pybus, OG, McLellan, JS, Wilson, IA, Bowden, TA, Ward, AB, Crispin, M
Aineistotyyppi:	Journal article
Kieli:	English
Julkaistu:	Springer Nature 2020

Samankaltaisia teoksia

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Tekijä: Yasunori Watanabe, et al.
Julkaistu: (2020-05-01)

Structure of the Lassa virus glycan shield provides a model for immunological resistance
Tekijä: Watanabe, Y, et al.
Julkaistu: (2018)

Antibodies expose multiple weaknesses in the glycan shield of HIV.
Tekijä: Crispin, M, et al.
Julkaistu: (2013)

Antibodies expose multiple weaknesses in the glycan shield of HIV.
Tekijä: Crispin, M, et al.
Julkaistu: (2013)

The impact of sequence diversity on the glycan shield of HIV-1 immunogens
Tekijä: Seabright, GE
Julkaistu: (2019)

Beyond Shielding: The Roles of Glycans in the SARS-CoV‑2 Spike Protein
Tekijä: Lorenzo Casalino, et al.
Julkaistu: (2020-09-01)

Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies.
Tekijä: Pritchard, L, et al.
Julkaistu: (2015)

Architecture of the HIV-1 glycan shield
Tekijä: Pritchard, L
Julkaistu: (2014)

Mapping the glycan shields of enveloped viruses
Tekijä: Watanabe, Y
Julkaistu: (2020)

Integrity of glycosylation processing of a glycan-depleted trimeric HIV-1 immunogen targeting key B-cell lineages
Tekijä: Behrens, AJ, et al.
Julkaistu: (2018)

The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2
Tekijä: Joel D. Allen, et al.
Julkaistu: (2023-04-01)

The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade.
Tekijä: Bonomelli, C, et al.
Julkaistu: (2011)

Glycosylator: a Python framework for the rapid modeling of glycans
Tekijä: Thomas Lemmin, et al.
Julkaistu: (2019-10-01)

N- and O-glycan analysis for the detection of glycosylation disorders
Tekijä: Amr Sobhi Gouda, et al.
Julkaistu: (2021-01-01)

Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies
Tekijä: Le, N, et al.
Julkaistu: (2016)

The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade.
Tekijä: Camille Bonomelli, et al.
Julkaistu: (2011-01-01)

Fine structure of the HIV-1 glycan shield
Tekijä: Behrens, A
Julkaistu: (2017)

Glycan shield of the ebolavirus envelope glycoprotein GP
Tekijä: Weiwei Peng, et al.
Julkaistu: (2022-08-01)

Conformational Heterogeneity of the HIV Envelope Glycan Shield
Tekijä: Mingjun Yang, et al.
Julkaistu: (2017-06-01)

Glycan Nanostructures of Human Coronaviruses
Tekijä: Guo W, et al.
Julkaistu: (2021-07-01)

Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection.
Tekijä: Sommerstein, R, et al.
Julkaistu: (2015)

Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection.
Tekijä: Rami Sommerstein, et al.
Julkaistu: (2015-11-01)

Synthesis of N-glycan oxazolines: donors for endohexosaminidase catalysed glycosylation.
Tekijä: Rising, T, et al.
Julkaistu: (2006)

Editorial: Glycobiology and glycosylation: deciphering the secrets of glycans in humans and pathogens
Tekijä: Parham Jabbarzadeh Kaboli, et al.
Julkaistu: (2025-02-01)

N-Glycosylation and N-Glycan Processing in HBV Biology and Pathogenesis
Tekijä: Mihaela-Olivia Dobrica, et al.
Julkaistu: (2020-06-01)

Glycosylation network mapping and site-specific glycan maturation in vivo
Tekijä: Marie-Estelle Losfeld, et al.
Julkaistu: (2022-11-01)

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies
Tekijä: Julien J, et al.
Julkaistu: (2012-09-01)

Glycan Positioning Impacts HIV-1 Env Glycan-Shield Density, Function, and Recognition by Antibodies
Tekijä: Qing Wei, et al.
Julkaistu: (2020-11-01)

Antibody evasion by a gammaherpesvirus O-glycan shield.
Tekijä: Bénédicte Machiels, et al.
Julkaistu: (2011-11-01)

Glycan Profile Analysis of Engineered Trastuzumab with Rationally Added Glycosylation Sequons Presents Significantly Increased Glycan Complexity
Tekijä: Esteban Cruz, et al.
Julkaistu: (2021-10-01)

Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26
Tekijä: Naveen Vankadari, et al.
Julkaistu: (2020-01-01)

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
Tekijä: Pejchal, R, et al.
Julkaistu: (2011)

Glycans instructing immunity: the emerging role of altered glycosylation in clinical immunology
Tekijä: Jonathan J Lyons, et al.
Julkaistu: (2015-06-01)

Multivalent interactions between fully glycosylated influenza virus hemagglutinins mediated by glycans at distinct N-glycosylation sites
Tekijä: Ruofan Li, et al.
Julkaistu: (2024-10-01)

Fine structure of the HIV-1 glycan shield - Supplementary information
Tekijä: Behrens, A
Julkaistu: (2017)

Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation
Tekijä: Tongqing Zhou, et al.
Julkaistu: (2017-04-01)

Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies
Tekijä: Muriel Lavie, et al.
Julkaistu: (2018-04-01)

Structural constraints determine the glycosylation of HIV-1 envelope trimers
Tekijä: Pritchard, L, et al.
Julkaistu: (2015)

Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.
Tekijä: Rajesh P Ringe, et al.
Julkaistu: (2023-10-01)

Controlled site-selective protein glycosylation for precise glycan structure-catalytic activity relationships.
Tekijä: Davis, B, et al.
Julkaistu: (2000)